Returning to work after multimodal treatment in glioblastoma patients
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
This should be a key endpoint for clinical trials for glioblastomas. In this study, only 18% of the patients went back to work after surgery, radiation and Temodar. Out of these who did go back to work, most were not able to resume full time work. Only about 8 out of the 125 patients were able to return to work full time. Some of the new experimental treatments such as DCVAX and Tocagen not only had some long term survivors, but had people working full time in high level jobs 5+ years after diagnosis. That is really what we want to see, even more than merely "surviving".
Posted on: 06/30/2018
Click HERE to return to brain tumor news headlines